BACKGROUND: The cell cycle checkpoint kinase 2 (CHEK2) gene I157T variant may be associated with an increased risk of breast cancer, but it is unclear whether the evidence is sufficient to recommend testing for the mutation in clinical practice. MATERIALS AND METHODS: We systematically searched PubMed, Embase, Elsevier and Springer for relevant articles published before Nov 2011. Summary odds ratio (OR) and 95% confidence interval (95% CI) incidence rates were calculated using a random-effects model with STATA (version 10.0) software. RESULTS: A total of fifteen case-control studies, including 19,621 cases and 27,001 controls based on the search criteria, were included for analysis. A significant association was found between carrying the CHEK2 I157T variant and increased risk of unselected breast cancer (OR = 1.48, 95% CI = 1.31-1.66, P < 0.0001), familial breast cancer (OR = 1.48, 95% CI = 1.16-1.89, P < 0.0001), and early-onset breast cancer (OR = 1.47, 95% CI = 1.29-1.66, P < 0.0001). We found an even stronger significant association between the CHEK2 I157T C variant and increased risk of lobular type breast tumors (OR = 4.17, 95% CI = 2.89-6.03, P < 0.0001). CONCLUSION: Our research indicates that the CHEK2 I157T variant may be another important genetic mutation which increases risk of breast cancer, especially the lobular type.
BACKGROUND: The cell cycle checkpoint kinase 2 (CHEK2) gene I157T variant may be associated with an increased risk of breast cancer, but it is unclear whether the evidence is sufficient to recommend testing for the mutation in clinical practice. MATERIALS AND METHODS: We systematically searched PubMed, Embase, Elsevier and Springer for relevant articles published before Nov 2011. Summary odds ratio (OR) and 95% confidence interval (95% CI) incidence rates were calculated using a random-effects model with STATA (version 10.0) software. RESULTS: A total of fifteen case-control studies, including 19,621 cases and 27,001 controls based on the search criteria, were included for analysis. A significant association was found between carrying the CHEK2I157T variant and increased risk of unselected breast cancer (OR = 1.48, 95% CI = 1.31-1.66, P < 0.0001), familial breast cancer (OR = 1.48, 95% CI = 1.16-1.89, P < 0.0001), and early-onset breast cancer (OR = 1.47, 95% CI = 1.29-1.66, P < 0.0001). We found an even stronger significant association between the CHEK2I157T C variant and increased risk of lobular type breast tumors (OR = 4.17, 95% CI = 2.89-6.03, P < 0.0001). CONCLUSION: Our research indicates that the CHEK2I157T variant may be another important genetic mutation which increases risk of breast cancer, especially the lobular type.
Authors: Miriam S Reuter; Susan Walker; Bhooma Thiruvahindrapuram; Joe Whitney; Iris Cohn; Neal Sondheimer; Ryan K C Yuen; Brett Trost; Tara A Paton; Sergio L Pereira; Jo-Anne Herbrick; Richard F Wintle; Daniele Merico; Jennifer Howe; Jeffrey R MacDonald; Chao Lu; Thomas Nalpathamkalam; Wilson W L Sung; Zhuozhi Wang; Rohan V Patel; Giovanna Pellecchia; John Wei; Lisa J Strug; Sherilyn Bell; Barbara Kellam; Melanie M Mahtani; Anne S Bassett; Yvonne Bombard; Rosanna Weksberg; Cheryl Shuman; Ronald D Cohn; Dimitri J Stavropoulos; Sarah Bowdin; Matthew R Hildebrandt; Wei Wei; Asli Romm; Peter Pasceri; James Ellis; Peter Ray; M Stephen Meyn; Nasim Monfared; S Mohsen Hosseini; Ann M Joseph-George; Fred W Keeley; Ryan A Cook; Marc Fiume; Hin C Lee; Christian R Marshall; Jill Davies; Allison Hazell; Janet A Buchanan; Michael J Szego; Stephen W Scherer Journal: CMAJ Date: 2018-02-05 Impact factor: 8.262
Authors: Maria I Carlo; Semanti Mukherjee; Diana Mandelker; Joseph Vijai; Yelena Kemel; Liying Zhang; Andrea Knezevic; Sujata Patil; Ozge Ceyhan-Birsoy; Kuo-Cheng Huang; Almedina Redzematovic; Devyn T Coskey; Carolyn Stewart; Nisha Pradhan; Angela G Arnold; A Ari Hakimi; Ying-Bei Chen; Jonathan A Coleman; David M Hyman; Marc Ladanyi; Karen A Cadoo; Michael F Walsh; Zsofia K Stadler; Chung-Han Lee; Darren R Feldman; Martin H Voss; Mark Robson; Robert J Motzer; Kenneth Offit Journal: JAMA Oncol Date: 2018-09-01 Impact factor: 31.777
Authors: Siddhartha Yadav; Chunling Hu; Katherine L Nathanson; Jeffrey N Weitzel; David E Goldgar; Peter Kraft; Rohan D Gnanaolivu; Jie Na; Hongyan Huang; Nicholas J Boddicker; Nicole Larson; Chi Gao; Song Yao; Clarice Weinberg; Celine M Vachon; Amy Trentham-Dietz; Jack A Taylor; Dale R Sandler; Alpa Patel; Julie R Palmer; Janet E Olson; Susan Neuhausen; Elena Martinez; Sara Lindstrom; James V Lacey; Allison W Kurian; Esther M John; Christopher Haiman; Leslie Bernstein; Paul W Auer; Hoda Anton-Culver; Christine B Ambrosone; Rachid Karam; Elizabeth Chao; Amal Yussuf; Tina Pesaran; Jill S Dolinsky; Steven N Hart; Holly LaDuca; Eric C Polley; Susan M Domchek; Fergus J Couch Journal: J Clin Oncol Date: 2021-10-21 Impact factor: 44.544
Authors: Johanna I Kiiski; Liisa M Pelttari; Sofia Khan; Edda S Freysteinsdottir; Inga Reynisdottir; Steven N Hart; Hermela Shimelis; Sara Vilske; Anne Kallioniemi; Johanna Schleutker; Arto Leminen; Ralf Bützow; Carl Blomqvist; Rosa B Barkardottir; Fergus J Couch; Kristiina Aittomäki; Heli Nevanlinna Journal: Proc Natl Acad Sci U S A Date: 2014-10-06 Impact factor: 11.205
Authors: Saud H AlDubayan; Louise C Pyle; Marija Gamulin; Tomislav Kulis; Nathanael D Moore; Amaro Taylor-Weiner; Anis A Hamid; Brendan Reardon; Bradley Wubbenhorst; Rama Godse; David J Vaughn; Linda A Jacobs; Stefanie Meien; Mislav Grgic; Zeljko Kastelan; Sarah C Markt; Scott M Damrauer; Daniel J Rader; Rachel L Kember; Jennifer T Loud; Peter A Kanetsky; Mark H Greene; Christopher J Sweeney; Christian Kubisch; Katherine L Nathanson; Eliezer M Van Allen; Douglas R Stewart; Davor Lessel Journal: JAMA Oncol Date: 2019-04-01 Impact factor: 33.006
Authors: Marta Kaczmarek-Ryś; Katarzyna Ziemnicka; Szymon T Hryhorowicz; Katarzyna Górczak; Justyna Hoppe-Gołębiewska; Marzena Skrzypczak-Zielińska; Michalina Tomys; Monika Gołąb; Malgorzata Szkudlarek; Bartłomiej Budny; Idzi Siatkowski; Paweł Gut; Marek Ruchała; Ryszard Słomski; Andrzej Pławski Journal: Hered Cancer Clin Pract Date: 2015-03-01 Impact factor: 2.857